In Vitro Intracellular Trafficking of Virulence Antigen during Infection by Yersinia pestis by DiMezzo, Tracy L. et al.
In Vitro Intracellular Trafficking of Virulence Antigen
during Infection by Yersinia pestis
Tracy L. DiMezzo
1, Gordon Ruthel
1, Ernst E. Brueggemann
2, Harry B. Hines
2, Wilson J. Ribot
1, Carol E.
Chapman
1, Bradford S. Powell
1, Susan L. Welkos
1*
1Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America, 2Integrated
Toxicology, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Maryland, United States of America
Abstract
Yersinia pestis, the causative agent of plague, encodes several essential virulence factors on a 70 kb plasmid, including the
Yersinia outer proteins (Yops) and a multifunctional virulence antigen (V). V is uniquely able to inhibit the host immune
response; aid in the expression, secretion, and injection of the cytotoxic Yops via a type III secretion system (T3SS)-
dependent mechanism; be secreted extracellularly; and enter the host cell by a T3SS-independent mechanism, where its
activity is unknown. To elucidate the intracellular trafficking and target(s) of V, time-course experiments were performed
with macrophages (MWs) infected with Y. pestis or Y. pseudotuberculosis at intervals from 5 min to 6 h. The trafficking
pattern was discerned from results of parallel microscopy, immunoblotting, and flow cytometry experiments. The MWs were
incubated with fluorescent or gold conjugated primary or secondary anti-V (antibodies [Abs]) in conjunction with organelle-
associated Abs or dyes. The samples were observed for co-localization by immuno-fluorescence and electron microscopy.
For fractionation studies, uninfected and infected MWs were lysed and subjected to density gradient centrifugation coupled
with immunoblotting with Abs to V or to organelles. Samples were also analyzed by flow cytometry after lysis and dual-
staining with anti-V and anti-organelle Abs. Our findings indicate a co-localization of V with (1) endosomal proteins between
10–45 min of infection, (2) lysosomal protein(s) between 1–2 h of infection, (3) mitochondrial proteins between 2.5–3 h
infection, and (4) Golgi protein(s) between 4–6 h of infection. Further studies are being performed to determine the specific
intracellular interactions and role in pathogenesis of intracellularly localized V.
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Introduction
Yersinia pestis, the causative agent of bubonic, septicemic, and
pneumonic plague, is a globally distributed pathogen [1,2]. There
currently is no licensed human vaccine that elicits effective
immunity to pneumonic plague, a severe and highly fatal form of
the infection. Greater knowledge of events and interactions
supporting infection and the pathogenesis will lead to the
development of vaccines and therapeutics that are effective against
both bubonic and pneumonic forms of plague.
Research in pursuit of these goals has revealed that fully virulent
strains of Y. pestis possess several plasmid-encoded proteins that are
major immunogens and/or virulence factors, including the Yersinia
outer proteins (Yops) and virulence antigen (V), which are found
on the 70 kb low-calcium response plasmid (pLcr) or pCD1 [3].
These proteins are essential for survival of the organism in
mammalian hosts [4–12]. The 10 kb pPst (pesticin) or pPCP
plasmid encodes plasminogen activator (Pla), a protein that is
critical to the establishment of systemic infection from a peripheral
site and is also thought to have an essential role in the development
of pneumonic plague [13–17]. The Yops are induced by growth at
37uC under low-calcium conditions, or by contact with host cells,
and are delivered via the multi-component type III secretion
system (T3SS) [12,18–21]. These effector proteins function to (1)
disrupt cellular processes such as phagocytosis via actin depoly-
merization (YopE, YopH, YopO, YpkA and YopT), (2) suppress
cytokine production and induce apoptosis (YopJ), or (3) resist
innate immunity (YopM) [22,23].
The highly immunogenic pLcr-encoded V is essential to the
virulence of Y. pestis and required for production of disease, making
it a major target for vaccine development [1,18,21,24–28]. V
promotes infection by suppressing the host’s ability to produce
inflammatory cytokines, recruit inflammatory cells, and form
granulomas in response to infection. Furthermore, V stimulates
production of anti-inflammatory cytokines such as interleukin (IL)-
10 [21,25,26,29,30]. As a structural component of the ‘‘injection’’
apparatus, or injectisome, V also is a regulatory protein required
for the expression, secretion, and entry of the cytotoxic Yops into
host cells by the T3SS [19,31,32]. In addition, V is the only pLcr-
encoded protein known to be secreted in large amounts into the
surrounding medium by yersiniae in contact with eukaryotic cells,
and is shown to offer significant protection against plague
challenge when given by itself to mice [19,20,24–26,29].
Alternatively, V can enter cells by a novel T3SS-independent
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inside host cells are not known. Further research is needed to
identify the enzymatic activities, host cell targets, and specific
immunosuppressive effects of this complex virulence protein. The
objectives of these studies were to discern the mechanism of the
T3SS- independent entry of V into the cell and to determine its
intracellular course. These goals prompted our effort to identify
possible intracellular host proteins targeted by V using immuno-
microscopy, density gradient centrifugation, and flow cytometry
co-localization studies. Because V appears to localize both
intracellularly and systemically in the host, compounds that
effectively block the interaction of V and its intracellular protein
target(s) could also be effective in impeding or preventing the
overall disease progression.
Results
Intracellular trafficking of V antigen as detected by
microscopy
The entry of V into eukaryotic cells, which was originally
demonstrated using HeLa cells infected with Y. pestis KIM strains
[34], was corroborated using cells infected with the Y. pseudotuber-
culosis V-producing recombinant Y. ptb. pTrcV strain. HeLa cells
infected with Y. ptb. pTrcV were stained with a fluorescent
fluorescein (FITC)-labeled anti-V Ab, whereas uninfected cells and
cells infected with the parent V-negative YpIII p(IB19) strain
showed only background levels of fluorescence, confirming the
internalization and specific staining of V (data not shown). Several
different approaches were then used to monitor the intracellular
movement of V during the course of infection. Time-course
experiments with samples collected at intervals over 6 h were
performed with murine J774A.1 (J774) MWs pretreated with
cytochalasin D (cytoD) to prevent phagocytosis [34,35]. Then
MWs were infected with V antigen-producing Yersinia strains,
including Y. ptb. pTcrV and Y. pestis strain CO92 pPst- pgm-,
each of which have an intact T3SS. Thus, some of the V detected
intracellularly may have been the result of Yersinia secretion
complex (Ysc)-associated V, based on findings of Fields and Straley
[34]. Therefore, to more specifically characterize the T3SS-
independent entry of V, Y. pseudotuberculosis strain YpIII p(IB604),
which contains a deletion in the yopB gene coding for a required
component of the T3S apparatus [36], and CO92 pPst- pgm- in
the presence of small molecule inhibitors (SMI) of T3S, were used
for infection. The presence of Yops was detected by staining with
the labeled Abs specific for YopM, YopE, YopH, and YopD (data
not shown). Uninfected and infected MWs were then incubated
with fluorescently-labeled Abs to organelle markers (Table 1) or V.
V was first detected intracellularly 10 min after infection with
CO92 pPst- pgm- (Fig. 1, panel A) or YpIII p(IB604) (Fig. 1, panel
G) in early endosomes, as indicated by the co-localization of
FITC-conjugated anti-V Ab and early endosomal antigen -1
(EEA-1) Abs (Table 1) in immunofluorescence microscopy
experiments (IFM). The antigen could be detected in early
endosomes during the first 30 min of infection. Subsequently, the
majority of anti-V Ab staining co-localized with that of Abs to late
endosomal markers, as represented in Fig. 1 panels B (CO92 pPst-
pgm), and H (CO92 pPst- pgm- with SMI), using M6P and rab7
respectively, after 30–45 min of infection. V appeared in
lysosomes between 1 and 2 h after infection, as identified by the
overlap in staining of LysoTracker and anti-V Ab, as illustrated for
CO92 pPst- pgm- (Fig. 1, panel C), and SMI-pretreated CO92
pPst- pgm- (Fig. 1, panel I) infected MWs. Afterward, V was
Table 1. Organelle-associated antibodies and markers.
Organelle Marker Abbreviation Source Secondary
Cytoplasm CellTracker Orange CMRA CellTracker Invitrogen n/a
Endoplasmic Reticulum anti-calreticulin n/a Abcam rhodamine
ER-Tracker BODIPY
b TR ER-Tracker Red Invitrogen n/a
ER-Tracker Green FL ER-Tracker Green Invitrogen n/a
Endosome anti-early endosome antigen-1 EEA-1 Abcam rhodamine
anti-mannose-6-phosphate receptor M6P Abcam FITC
anti-rab7 Rab 7 Abcam rhodamine
Golgi beta-cotamer protein b-cop Abcam rhodamine
Green-fluorescent BODIPY
b FL C5 ceramide Brefeldin A Invitrogen n/a
Brefeldin A BODIPY
b 568/668 Ceramide Invitrogen n/a
anti-Golgin-97 Golgin-97 Invitrogen n/a
Alexa Fluor 594 wheat germ agglutinin WGA Invitrogen n/a
Lysosome anti-lysosome-associated membrane protein-1 Lamp-1 Abcam rhodamine
anti-lysosome-associated membrane protein-2 Lamp-2 Abcam rhodamine
LysoTracker Red DND-99 LysoTracker Invitrogen n/a
Mitochondria MitoTracker Red CXRos MitoTracker Invitrogen n/a
anti-voltage-dependent anion channel-1 VDAC-1 Abcam rhodamine
Nucleus 49, 6-diamidino-2-phenylindole DAPI Sigma n/a
H1 histone n/a Novus rhodamine
Peroxisome anti-catalase Catalase Abcam rhodamine
aNot Applicable.
bBoron Dipyromethene Difluoride.
doi:10.1371/journal.pone.0006281.t001
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MitoTracker and anti-V Ab staining, from 2.5–3 h of infection,
as seen in Fig. 1. panels D (CO92 pPst- pgm-) and J (YpIII
p[IB604]). Similar results were observed with SMI-pretreated
CO92 pPst- pgm- and Y. ptb. pTcrV infected MWs under the
same conditions (data not shown). Furthermore, Ab co-localization
experiments showed that after 4 h, V had associated with Golgi
apparatus markers in MWs, including b-cop (data not shown),
BODIPY ceramide (Fig. 1, panel F [CO92 pPst- pgm-]), golgin-97
(data not shown), or with trans-Golgi marker WGA in J774 MWs
(Fig. 1, panels E [CO92 pPst- pgm-] and K [YpIII p{IB604}]). V
remained in the Golgi, as monitored by the co-localization of the
Golgi markers (Table 1) and anti-V Ab, until after 6 h of infection,
when decreasing cell viability prevented the determination of
localization. Conversely, MWs infected with the V-negative strain
YpIII p(IB19) showed no overlap of staining with anti-V Ab and
the organelle markers, including MitoTracker, after 3 h of
infection (Fig. 1, panel L). In addition, no observable overlap in
staining between anti-V Ab with catalase, histone H1, CellTracker
Orange, ER-Tracker Red dye, or calreticulin Ab (data not shown)
(Table 1) was detected at any of the time intervals tested. These
results suggested V did not co-localize to the peroxisomes, nuclei,
cytoplasm, or endoplasmic reticulum (ER), respectively.
In addition to IFM, immunoconfocal microscopy (ICM)
performed on MWs infected for 3 h with CO92 pPst- pgm-
demonstrated the staining of individual mitochondria with
MitoTracker (Fig. 2, panel A, column 1), and of V antigen with
FITC-conjugated anti-V (Fig. 2 panel A, column 2). Merging of
the images suggested the presence of V in individual mitochon-
dria (Fig. 2, panel A, column 3), a finding which was in
agreement with IFM experiments. When MWs were infected for
4 h and stained with anti-V Ab or WGA, the resulting merged
ICM images demonstrated a perinuclear association of V in the
trans-Golgi network (Fig. 2, panel B), supporting our previous
IFM results. As a control for staining, uninfected MWs were
incubated with FITC anti-V, FITC-labeled anti-mouse IgG, and
Alexa Fluor 488 labeled anti-rabbit IgG Abs. Infected MWs were
incubated with FITC anti-mouse/Alexa Fluor 488 anti-rabbit
Abs. Only background levels of staining were observed (data not
shown).
Figure 1. Trafficking of V as detected by IFM. MFs were infected with Yersinia for different periods of time. The infecting Yersinia strain was
C092 pPst- pgm- (panels A–F, H and I), Y pIII p(IB604) (panels G, J, and K); or YpIII p(IB19) (panel L). In panels H and I, SMI of T3S were added to CO92
pPst- pgm- prior to infection. IFM images depicted infected, cytoD-pretreated MWs stained with organelle markers (Table 1), including EEA-1 Ab
(panels A and G) at a 10 min infection, M6P Ab (panel B) or rab7 Ab (panel H) at a 45 min infection, LysoTracker (panels C and I) at a 1 h infection,
MitoTracker (panels D, J, and L) at 3 h infections, and/or anti-V Ab at all time points. MFs were infected for 4 h, stained with BODIPY ceramide (panel
F) or WGA (panel E and K) after 4 h of infection, followed by anti-V staining. Co-localization was defined by yellow/orange regions, suggesting the
presence of green and red fluorescence, which was observed at different sites during the course of infection, i.e., in early endosomes after 10 min,
late endosomes after 30–45 min, lysosomes after 1–2 h, mitochondria after 2.5–3 h, and the Golgi apparatus after 4 h. Scale bar=10 micrometers
(mm) (panels A–E, and G–L) and 5 mm (F).
doi:10.1371/journal.pone.0006281.g001
Trafficking of LcrV
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6281To determine if V was trafficking from lysosomes to
mitochondria and Golgi sequentially or simultaneously, MWs
were pretreated with cytoD, Ru360 (an inhibitor of mitochondrial
function), or both for 30 min before infection with YpIII p(IB604).
MW pretreatment with Ru360 in the presence of cyto D did not
appear to alter V’s localization to the mitochondria after 2.5–3 h
of infection, as monitored by anti-V Ab and MitoTracker staining
(data not shown). After 4 h of infection in the presence of cyto D
alone, MWs stained with WGA and then by FITC anti-V Ab
demonstrated co-localization of V with Golgi protein(s) (Fig. S1,
panel A), as observed in Fig. 1 (panels E and K. However, in the
presence of Ru360 alone, V staining was intensely distributed
throughout the cells, making it difficult to observe discrete MWs
(Fig. S1, panel B). When both inhibitors were present, no anti-V
staining was observed (Fig. S1, panel C), results which may suggest
that V traffics from the mitochondria to the Golgi in succession.
Co-localization of anti-V Ab with organelle-markers was
analyzed quantitatively in JACoP, an Image J plugin, using
Pearson’s correlation coefficients (PCCs) and Mander’s overlap
coefficients (MOCs), after correcting for background. For
endosomal marker EEA-l Ab, PCCs were calculated to be
r=0.959 (CO92 pPst- pgm-) and r=0.928 (YpIII p[IB604]), after
10 min of infection. These results suggested that co-localization
occurred between anti-V and EEA-1 Abs (Table 2), since co-
localization increases as the coefficients approach 1 [37,38]. The r
2
values expressed as percentages indicated that 92.0% of the MWs
infected with CO92 pPst- pgm- and 86.1% of MWs infected with
YpIII p(IB604) demonstrated co-localization between EEA-1 and
anti-V Ab staining. Corresponding results derived using the MOC
on the same images indicated r=0.941 (CO92 pPst- pgm-) and
r=0.946 (YpIII p[IB604]). This analysis was repeated for M6P,
rab7, LysoTracker, MitoTracker, and WGA at 45 min, 1 h, 3 h,
and 4 h respectively (Table 2), yielding results that indicated the
majority of anti-V Ab staining overlapped with the staining of each
of these organelle-associated markers. PCCs of r=0.017 and
r=0.126 were calculated for CO92 pPst- pgm- or YpIII p(IB604)
infected MWs, respectively, (Table 2), expressing less than 1% co-
localization.
To determine at an ultrastructural level if V was present in the
early endosomes, MWs were infected with CO92 pPst- pgm- for
15 min, 30 min, and 3 h, followed by staining with gold labeled
anti-V Ab (6 nanometers [nm]) and 15 nm gold-labeled Abs to
EEA-1, M6P, or VDAC-1 for immunoelectron microscopy (IEM)
analysis. Anti-V Ab gold particles were found in close proximity to
EEA-1 and M6P Abs near the MW cell membrane, supporting the
IFM observations (data not shown). Likewise, after 3 h of
Figure 2. Trafficking of V as detected by ICM. (A) MWs were infected for 3 h with CO92 pPst- pgm- and then stained with MitoTracker and FITC
conjugated anti-V Ab followed by Hoechst 33342 dye. (B) MWs were stained with Alexa Fluor 594-labeled WGA, infected with CO92 pPst- pgm- for
4 h, and stained with FITC anti-V Ab, followed by secondary staining with FITC-labeled anti-mouse IgG, and tertiary staining with Alexa Fluor 488
labeled anti-rabbit IgG Abs. MWs were also stained with Hoechst 33342 Dye. All images were captured with a BioRad 2000MP multiphoton confocal
system attached to a Nikon TE300 inverted microscope and merged in last panel. Co-localization was defined by an overlap of red and green staining,
suggesting V was present in mitochondria and Golgi, after 3 and 4 h of infection, respectively. Scale bar=5 mm.
doi:10.1371/journal.pone.0006281.g002
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mitochondria, marked by VDAC-1 (data not shown).
Intracellular trafficking of V antigen as detected by
gradient fractionation and immunoblotting
Lysates of uninfected MWs and MWs infected for various times
were fractionated by centrifugation and evaluated by gel
immunoelectrophoresis. After 15 min of infection with YpIII
p(IB604) (Fig. 3, panel A), a band recognized by anti-V mAb was
observed in the fraction that also was detected by EEA-1 Ab
(180 kD). Fractions that revealed bands when stained with anti-V
Abs also demonstrated staining with (1) late endosomal antigen
M6P (31kD) after 30 min of infection with SMI-pretreated CO92
pPst- pgm- (Fig. 3, panel B), (2) lysosomal marker Lamp-1
(120 kD) after 2 h with SMI-pretreated CO92 pPst- pgm- (Fig. 3,
panel C), (3) mitochondria protein VDAC-1 (31 kD) after 3 h
(Fig. 3, panel E) with (a) CO92 pPst- pgm-, (b) Y. ptb. pTcrV, or
(c) YpIII p(IB604), and (4) Golgi marker b-COP after 4 h infection
with CO92 pPst- pgm- (Fig. 3, panel G). However, fractions
immunoblotted with the organelle-associated markers described in
Table 1 did not demonstrate bands in fractions stained with anti-V
Abs at any other time intervals tested. Representative blots (Fig. 3,
panel D) are depicted, showing anti-V Ab staining in the latter
fractions, i.e. heavier fractions, which did not align with the
calreticulin Ab (,63 kD) stained bands, after 3 h of infection. As
shown in Fig. 3, panel F, MFs that were not pretreated with cytoD
Table 2. Co-localization analysis of IFM intracellular V
trafficking.
Organelle Strain
Pearson’s
(r=)
Mander’s
Overlap (r=)
EEA-1 CO92 pPst- pgm- 0.959 0.941
YpIII p(IB604) 0.928 0.946
M6P CO92 pPst- pgm- 0.983 0.979
YpIII p(IB604) 0.974 0.970
Rab7 CO92 pPst- pgm- 0.921 0.941
YpIII p(IB604) 0.908 0.926
LysoTracker CO92 pPst- pgm- 0.871 0.880
YpIII p(IB604) 0.846 0.841
MitoTracker CO92 pPst- pgm- 0.951 0.957
YpIII p(IB604) 0.964 0.925
WGA CO92 pPst- pgm- 0.852 0.864
YpIII p(IB604) 0.888 0.886
Catalase CO92 pPst- pgm- 0.017 0.001
YpIII p(IB604) 20.126 0.005
doi:10.1371/journal.pone.0006281.t002
Figure 3. Trafficking of V as detected by density gradient centrifugation and immunoblot analysis. MFs were infected with CO92 pPst-
pgm- (panels D-E-a, F-a-b, and G), SMI-pretreated CO92 pPst- pgm- (panels B, C, and F-c), or YpIII p(IB604) (panels A, E-c and E-e) for 15 min, 30 min,
2 h, 3 h, or 4 h. The fractions, or purified V (approx. 35 kD), were immunoblotted with anti-V Ab or with organelle-associated markers. The latter
included Abs to EEA-1 (180 kD), M6P (31 kD), Lamp-1 (120 kD), VDAC-1 (31 kD), calreticulin (,63 kD) and b-COP (81 kD). After infection for 15 min
(panel A), a band recognized by the anti-V mAb was observed in fractions that also contained bands detected by EEA-1 Ab. Similar patterns were
observed for anti-V and Abs to: (panel B) M6P after 30 min of infection, (panel C) Lamp-1 after 2 h, (panels E) VDAC-1 after 3 h, and (panel G) b-COP
after 4 h. At all time intervals tested, calreticulin (,63 kD) was not observed immunologically in fractions recognized by anti-V; a representative blot
is shown in panel (D). MWs were also infected with for 3 h with Y. ptb. pTcrV (Panel E-b) or with the V-negative strain YpIII p(IB19) for 3 h (Panel E-d).
In panel F, immunoblots were developed using anti-YopM Ab, to detect YopM in MFs that were not treated with cytoD (Panel F-a), treated with
cytoD (Panel F-b), or treated and infected with SMI treated CO92 pPst- pgm- (Panel F-c) are shown.
doi:10.1371/journal.pone.0006281.g003
Trafficking of LcrV
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corresponding to anti-YopM Ab staining (panel F-a), the quantity
of which was reduced by the addition of cytoD (panel F-b), and
eliminated when CO92 pPst- pgm- was pretreated with SMI
before infection (panel F-c). Additionally, none of the fractions
demonstrated staining with anti-Yop D, anti-Yop E, or anti-Yop
H Abs when SMI of T3S were present (data not shown). In
contrast, MWs infected for 3 h with YpIII p(IB19) yielded no
fractions recognized by anti-V Ab (Fig. 3, panel E-d) on the
immunoblots, even though mitochondrial proteins were present
(Fig. 3, panel E-e). Thus, the results suggested that early and late
endosomal proteins were present in fractions containing V after
15–30 min of infection. Subsequently, V was present in fractions
containing lysosomes after 1 h (data not shown) and 2 h,
mitochondria after 3 h, and cis-Golgi after 4 h, as determined
by anti-V Ab and organelle-associated marker immunoblotting.
However, V does not appear to have localized to fractions
containing ER, nuclei, or cytoplasm (as suggested by IFM), or
peroxisomes at any of the time intervals tested.
Intracellular trafficking of V antigen as detected by flow
cytometry
Uninfected and infected samples were lysed, stained with anti-V
and/or organelle-associated markers, and analyzed by flow
cytometry. Fluorescence was plotted as FL-1 (green) vs. FL-2
(red) channel pseudocolor dot plots in FlowJo (version 7.1.2). Two
populations, one each representing FL-1 and FL-2 channel
detected fluorescence, were observed when no co-localization
was present. A single population detected by both the FL-1 and
FL-2 channels was considered to represent co-localization. For all
experiments anti-V/FITC Abs (FL-1 channel) were used, expect
for M6P Ab stained samples, which were stained with unconju-
gated anti-V mAb followed by rhodamine conjugated goat anti-
mouse IgG and were detected in the FL-2 channel. Organelles
isolated from MWs infected with CO92 pPst- pgm- for 15 min
were stained with FITC-anti-V Ab and Abs to organelle markers.
Analysis on a BD FACSCalibur Flow Cytometer revealed a single
population detected by the FL-2 channel (84.33%) when the
organelles were stained with EEA-1 Ab alone (Fig. 4, panel A row
1). When stained with anti-V Ab alone, 97.87% of the organelle
population represented FL-1 fluorescence (Fig. 4, panel A, row 2).
However, when EEA-1 and anti-V Abs were both present, a single
population (80.75%) was detected by both channels (Fig. 4, panel
A, row 3), suggesting co-localization. Thus, the results confirmed
earlier IFM and immunoblot experiments that showed an
association of V with early endosomes during the first 10–
15 min of infection. Similar finding were observed when
organelles were infected with CO92 pPst- pgm- or YpIII
p(IB604) and stained with the associated organelle-markers at
the time intervals established in the IFM and immunoblotting
Figure 4. Trafficking of V as detected by flow cytometry. MFs were infected with either CO92 pPst- pgm- (panels A–E, G) or Y.pIII pIB604
(panel H); alternatively, LFnV (Panel F) was delivered with PA for different periods of time. Panel (A): MFs were infected for 15 min and stained with
EEA-1 and anti-V Abs. Panel (B): MFs were infected for 30 min, stained with M6P and anti-V Abs. Panels (C and D): MFs were infected for 2 h followed
by staining with LysoTracker or ER-Tracker Red, respectively, and anti-V Ab. Panel (E): MFs were infected for 2.5 h, stained cells with MitoTracker,
followed by anti-V Ab. Panel (F): MFs were exposed to LFnV for 4 h, stained with MitoTracker, followed by anti-V Ab. Panel (G and H): MFs were
stained for 30 min with WGA, infected for 4 h, and stained with anti-V Ab. Co-localization was defined by a population shift to region 3.
doi:10.1371/journal.pone.0006281.g004
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panels A-E, and G) and YpIII p(IB604) (Fig. 4, panel H) are
shown, stained with anti-V Abs and (1) M6P Ab/FITC goat anti-
chicken after 30 min (Fig. 4, panel B), (2) LysoTracker after 2 h
(Fig. 4, panel C), (3) MitoTracker after 2.5 h (Fig. 4, panel G), and
(4) WGA after 4 h of infection (Fig. 4, panel H). For samples
stained with both M6P and anti-V Abs, region 3 (Fig. 4, panel B,
row 3) represented the largest percentage (54.87%). This
population was detected in both the FL-1 and FL-2 channels,
suggesting co-localization of V in the late endosomes. Region 2,
which represented the population stained by anti-V alone as
recognized by only the FL-2 channel, comprised less than 1% of
the total population. These results indicated that almost all of the
anti-V Ab staining was accounted for in region 3. However,
38.40% of the late endosomes had no V present, suggested by the
population observed in region 1, which was detected in the FL-1
channel alone and corresponded to M6P Ab staining. In contrast
to the above findings, no co-localization was observed with anti-V
Abs and any of the organelle-associated markers at any other time
interval tested, including the endoplasmic reticulum, stained with
ER-Tracker Red (Fig. 4, panel D) and peroxisomes, stained with
catalase Ab (data not shown). Those MWs infected with YpIII
p(IB19), the V-negative strain, lacked a FL-1 channel population
when stained with anti-V Abs.
A quantitative analysis based on the percentages of one- and
two-stained populations supported our findings, as profiled in
Fig. 5. For the three regions plotted, a post ANOVA (analysis of
various) t-test revealed statistically significant differences in region
3 between samples stained with anti-V Ab alone, as compared to
those stained with both the organelle-associated marker and anti-
V Ab for EEA-1 (P,0.001), M6P (P,0.001), LysoTracker
(P,0.001), MitoTracker (P,0.05), and WGA (P,0.001) at the
specified time intervals. No significant differences (P.0.05) were
detected in region 3 when samples were stained with ER-Tracker
or catalase and anti-V Abs, as compared to anti-V Ab staining
alone. These data substantiate our IFM and immunoblotting
results by a third independent method.
As an alternate to infection for the demonstration of V
trafficking, the lethal factor (LF) and protective antigen (PA) from
Bacillus anthracis was used to shuttle V (LFnV-PA system) to MFs,
and the interaction was evaluated by flow cytometry. The co-
localization of MitoTracker and anti-V Ab was observed after 4 h
incubation with LFnV-PA (Fig. 4 panel F).
After 6 h of infection, cell viability decreased significantly, as
detected by IFM, and V was not tracked beyond the Golgi apparatus.
Thus, flow cytometry was utilized to evaluate any effect of V on cell
viability. MWs were infected with all strains for 4–12 h at intervals of
1 h, including CO92 pPst- pgm- and Y. ptb. pTcrV in the presence/
absence of SMI of T3S. Cytotoxicity was measured by propidium
iodide (PI)/Syto-13 or DEADRed/Syto-10 staining. A 2-way
ANOVA comparison showed that there were significant differences
(P,0.05) between live and dead populations of uninfected and
infected MFs. Results of statistical analyses indicated that Yersinia
strains with an intact T3SS were significantly more cytotoxic
(P,0.001) after 5 h of infection, as compared to MWsi n f e c t e dw i t h
the V-negative strain, YpIII p(IB19) (Fig. S2). There were no
significant differences observed between YpIII p(IB19) infected MWs
and(1)YpIIIp(IB604) or (2)CO92pPst- pgm- in the presenceofSMI
of T3S, which may indicate V has a minimal role in cellular
cytotoxicity. However, there was a significant difference in the
cytotoxicity associated with MWs infected with SMI-pretreated Y.
ptb. pTcrV infected compared to that with the YpIII p(IB19) strain.
Figure 5. Region statistics of flow cytometry data. Percentages of flow cytometry fluorescence detected in the FL-1 only (region 1), FL-2 only
(region 2), or both (region 3) channels, which included infected organelles stained with organelle-associated markers alone, anti-V alone, or both,
were plotted. Post ANOVA t-tested indicated significant increases in the percentage of those isolated organelles that demonstrated both organelle
and anti-V Ab staining in region 3 as compared to anti-V Ab staining alone, as observed in those organelles stained with both anti-V Ab and EEA-1 Ab
(***, P,0.001), LysoTracker (P,0.001), MitoTracker (*, P,0.05), or WGA (P,0.001), suggesting co-localization. No significant increase in a double-
stained population was observed when isolated organelles were stained with both catalase and anti-V Abs.
doi:10.1371/journal.pone.0006281.g005
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Using an in vitro HeLa infection model, Fields and Straley (1999)
showed that V is not only required for the T3SS-mediated host cell
targeting and entry of the effector Yops, but that it also is capable
of entering these cells by a novel T3SS-independent pathway.
During their production and T3SS-facilitated transfer into host
cells, the effector Yops (YopE, YopH, YopJ, YopM, YpkA, and
YopT) are not secreted into the medium [2,20]. In contrast, V not
only partitions to the target cell cytosol, but also localizes to the
bacterial surface where it is an integral component of the T3SS
injectisome: Specifically V is found at the tip [32] and in
substantial amounts in the extracellular medium. Although it is
also contact-activated, the localization of most of the V to the
cytosol does not involve the T3SS. This finding as reported by
Fields and Straley [34] was evidenced by infections with strains
lacking a functional T3SS apparatus or the pLcr plasmid, which
encodes the T3SS components. In addition, the V that localizes
within the target cell was not the result of secretion into the culture
medium. Therefore, the authors concluded that a novel, contact-
activated, T3SS-independent pathway exists. This mechanism for
host cell transfer of V was hypothesized to involve non-pLcr-
encoded proteins that compose a ‘‘LcrV-transporting contact-
activated translocator (VCAT [34]),’’ which spans the bacterial
surface membranes and then, directly or indirectly, transfers V to
the target cell. Little is known about the composition of this
translocator, other proteins that might traverse it, the mechanism
of eukaryotic host cell internalization, or the function of the
internalized V. Our objectives were to identify how V enters the
host by T3SS-independent means, determine its trafficking
pattern, and understand localization within the cells, so as to
ultimately help identify the host protein(s) with which it interacts.
Several assays were developed herein to monitor V over the
course of infection of in vitro cell cultures. Recently, Y. pestis was
confirmed to target immune cells, the majority of which are MWs
and neutrophils [39]. As a result, our experiments focused on MWs
infected with the attenuated Yersinia strains in the presence of
cytoD to prevent bacterial invasion [33,39,40]. This in vitro model
of infection by virulent Y. pestis was used to investigate the extent of
intracellular V trafficking. Yersinia species utilize the Ysc injecti-
some during T3S, which includes three major components at the
tip (YopB, YopD, and LcrV). These proteins allow the cytotoxic
Yops to penetrate the host cell [41,42]. In addition to Y. pestis
CO92 pPst- pgm-, MWs were infected with the Y. pseudotuberculosis
YpIII p(IB604) strain, a mutant with a deletion in the yopB gene,
which, along with YopD and LcrV, is a critical determinant of the
host cell translocation pore. The absence of YopB thus blocks
delivery of Yops [36,43]. This mutant was used to confirm that the
V, which we observed intracellularly by microscopy, immuno-
blotting, and flow cytometry, was translocated by a T3SS-
independent mechanism. Using small molecule inhibitors of the
T3S we were able to confirm these findings with both Y.
pseudotuberculosis and Y. pestis strains. The presence of V was
confirmed in all strains tested (Fig. 3, panels E-a, E-b, and E-c),
except the V-negative YpIII p(IB19) (Fig. 3, panel E-d), which
showed a single band detected by anti-V Ab only in the lane
containing purified V, a positive control. Whereas Yops could also
be detected in MWs infected with the T3SS-proficient CO92 pPst-
pgm-, they did not appear to be translocated by the YpIII p(IB604)
strain (data not shown) or by the SMI-pretreated CO92 pPst-
pgm- strain (Fig. 3, panel F-c). Results of experiments with YpIII
p(IB604) and SMI-pretreated CO92 pPst- pgm- confirmed those
obtained in the initial experiments with the untreated CO92 pPst-
pgm- strain, suggesting that V becomes endocytosed by MWs and
traffics to the mitochondria and Golgi apparatus, in a manner that
is independent of Yops translocation.
Our results suggest that V followed an endocytic-associated
pathway and co-localized with endosomal proteins between 10–
45 min of infection, followed by lysosomal protein(s) between 1–
2 h. After 2.5–3 h of infection, V was observed in conjunction
with mitochondrial proteins, and subsequently with Golgi
protein(s) between 4–6 h of infection. Although we have not yet
determined which type of endocytic pathway is involved, the V
trafficking sequence we determined, summarized in Table 3, was
discerned from the concordance of results from parallel micros-
copy, immunoblot, and flow cytometry analyses of MWs infected
with V -producing Y. pestis and Y. pseudotuberculosis strains.
Intracellular V trafficking was not observed after 6 h of infection,
due to a decrease in cell viability. V may play a role in MW
viability, since flow cytometry analysis of SMI-pretreated Y. ptb.
pTcrV infected MWs demonstrated significant differences in cell
death as compared to MWs infected with a V-negative strain;
however, further research is necessary to clearly define intracel-
lular V’s function. Recent preliminary studies were performed
using Ru360, which selectively affects mitochondrial Ca
2+
transport [44,45], and appeared to prevent the trafficking of V
to the Golgi apparatus. This observation suggests that the
trafficking that we discerned is sequential and is not a result of
simultaneous localization to the mitochondria and Golgi. The
intense anti-V Ab staining observed in MWs pretreated with
Ru360 alone was likely the result of V detection on the
internalized bacterium’s surface (either directly associated or
present in association with the T3S system components). Further
research will be performed utilizing other inhibitors to confirm our
results, although most mitochondrial inhibitors nonspecifically
influence other cellular processes or induce apoptosis. In our
studies, markers specific to each organelle were selected when
possible, but due to the dynamic trafficking and recycling of
proteins, not all markers belonged solely to one organelle.
Consequently, we chose several markers for each organelle to
strengthen the likelihood that the overlap in staining we observed
was due to V localization to that organelle. For instance,
differentiating late endosomes from lysosomes can be problematic.
The M6P receptor antibody was chosen as a marker for late
endosomes despite the presence of these receptors in pre-lysosomes
[46,47] and the trans-Golgi network [48–50]. Thus, we chose an
additional marker, rab7, which is associated with late endosomes
[51–53]. Despite any potential issues with marker specificity,
neither our lysosomal markers (LysoTracker, Lamp-1, and Lamp-
2), nor our trans-Golgi marker, WGA, indicated co-localization
with anti-V Ab after 30–45 min of infection as was observed with
our M6P and rab7 Abs. As a result, we considered V to be present
in the late endosomes after 30–45 min of infection.
MWs infected with the V-negative YpIII p(IB19) strain
demonstrated no staining by anti-V Ab in IFM, immunoblots,
or flow cytometry analysis, regardless of the organelle-associated
marker at any given time point. Finally, the results of the MW
infection experiments were generally supported by flow cytometry
analysis in which V was delivered to the MWs by the LFnV-PA
system. Anthrax PA binds LF, triggering endocytosis of the PA-LF
complex which traffics to the endosomes via the endocytic
pathway. The toxic protein is then translocated across the
endosomal membrane and released into the cytoplasm [54,55].
The system involving the PA-mediated delivery of a protein fused
to the nontoxic LFn moiety into mammalian cells has been
exploited to deliver proteins, especially toxins such as diphtheria
toxin [56]. V was observed to traffic to the mitochondria after a
4 h incubation with LFnV-PA, as shown by flow cytometry (Fig. 4,
Trafficking of LcrV
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MF infection protocol, in which anti-V Ab co-localized with the
mitochondrial markers after 2.5–3 h of infection. This variation in
the timing of V-host compartment interactions most likely stems
from a difference in the kinetics of V trafficking that occurs when
V is translocated during a natural infection compared to that by
PA-mediated uptake. The kinetics of LFn- mediated internaliza-
tion and trafficking have not yet been determined. Regardless of
these differences, the results of both the infection model and of the
PA-mediated transfer system verify that V can enter host cells by a
T3SS-independent method and exhibit a specific linear sequence
of trafficking within these cells.
Eukaryotic cell processing of internalized material classically
involves transport from early to late endosomes, and then to
lysosomes where degradation typically occurs. In contrast,
internalized bacteria, viruses, and toxins often bind, enter cells,
and traffic intracellularly by alternative and distinct pathways [57–
63]. As discussed by Johannes and Decaudin [59], toxins utilize
various pathways of entry (clathrin-dependent and -independent)
and several endocytic pathways for intracellular trafficking, a
capacity termed ‘‘endocytic plasticity’’ [60,64]. For instance,
diphtheria toxin and the Shiga toxin-related protein toxins (Shiga
toxin, ricin, and cholera toxin) enter cells by various clathrin-
dependent or -independent mechanisms which can involve raft-
type membrane microdomains [59–61,64–71]. After entry, the
toxins of the Shiga family and Pseudomonas ExoA (PE) traffic from
the early endosomes to the Golgi apparatus by various routes and
bypass the late endosomes/lysosmes stage, which would otherwise
lead to degradation [59,64,70–76].
Several microbes or their toxic proteins exhibit endocytotic
trafficking patterns that have similarities to the pattern we
described for the Yersinia V protein. After gaining entry by
endocytosis they fuse with early and late endosomes, and during
subsequent inter-organelle migration, induce a chain of events that
often results in necrosis. For example, the movement of Salmonella
typhi in infected cells appears to involve a pattern of vesicular
trafficking via endosome and lysosomes [77]. This infection is also
associated with the induction of apoptosis, a process requiring the
permeabilization of the mitochondrial membrane [58] and which
may serve as a possible model for V trafficking. Also, the
gastrointestinal pathogen Helicobacter pylori exhibits some patho-
genic attributes similar to those of the Yersinia spp. Observations
reported using an in vitro model of gastric epithelial cell infection
indicate that, like V, H. pylori exhibits a pattern of early to late
endosomal trafficking. However, the VacA toxin of H. pylori causes
a disruption of the subsequent events in the endocytic pathway by
preventing maturation of late endosomes to lysosomes, a process
that likely promotes bacterial survival in the gastric epithelium
[60,63]. The results of studies with a HeLa cell model revealed
that VacA also can enter cells, traffic to the mitochondria, and
then modulate mitochondrial membrane permeability by a
mechanism affecting channel activity. This perturbation results
in the release of cytochrome C to the cytosol. These activities are
associated with the mitochondrial-mediated apoptotic pathway,
and the VacA model represents a novel mechanism for regulation
of this pathway by a bacterial toxin [78]. Thus, these systems could
potentially provide further insights for our ongoing studies to
define V trafficking.
The role played by internalized V antigen in the pathogenesis of
plague is unknown. Once candidate V-target interactions are
identified, in vitro and in vivo investigations will be done to analyze
the role and importance of the intracellular localization of V in the
pathogenesis of infection by Y. pestis. The final goal of these studies
is to leverage this newly characterized activity of V to develop
more specific and effective therapeutics and prophylactics against
plague.
Materials and Methods
Bacterial strains, reagents, and cell lines
Strains of Yersinia used included a pgm-, pPst- cured mutant of
the C092 strain of Y. pestis (CO92 pPst
2 pgm
2) and Y.
Table 3. Summary of intracellular V trafficking.
Marker 15 min 30 min 45 min 1 h 2 h 3 h 4 h 5 h 6 h
CellTracker
Calreticulin 2222 2 2 2 2 2
ER Tracker 2222 2 2 2 2 2
EEA-1 ++2 2 222 2 2
M6P 2 ++2 222 2 2
b-cop 2222 2 2 +++
Brefeldin A 2222 2 2 +++
Golgin-97 2222 2 2 ++2
WGA 2222 2 2 +++
Lamp-1 222++ 22 2 2
Lamp-2 222++ 22 2 2
LysoTracker 222++ 22 2 2
MitoTracker 2222 2 + 222
VDAC-1 2222 2 + 222
DAPI 2222 2 2 2 2 2
H1 histone 2222 2 2 2 2 2
Catalase 2222 2 2 2 2 2
doi:10.1371/journal.pone.0006281.t003
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deletion mutation of the plasmid pLcr-encoded lcrV gene, and
strain Y. ptb. pTcrV, which is transformed with the recombinant
pTrc99A-LcrV expression plasmid [20,27]; the YpIII p(IB19)-
derivative strains were kindly provided by J. Hill. Y. pseudotuber-
culosis strain YpIII p(IB604), harboring an in-frame deletion of the
yopB gene, was kindly provided by R. Nordfelth and H. Wolf-
Watz. Six SMIs of the T3SS, compounds 3, 8, 10–11, 17, and 21
[36,43] were generously provided by Dr. M. Elofsson at Umea
University (Sweden). Monoclonal Abs against V were IgG-purified
via high performance liquid chromatography from hybridoma
culture supernatants and assessed for binding by ELISA, as
described previously [24]. Biotinylated- and FITC-conjugated
derivatives of anti-V Ab (clone val3) were obtained from Hytest
(Finland). The J774 MW-like cell line was maintained in
Dulbecco’s modified Eagle’s minimum essential medium with
10% heated killed fetal bovine serum (FBS). HeLa cells, a human
carcinoma epithelioid cell line, were maintained in Roswell Park
Memorial Institute medium supplemented with 10–20% heat-
inactivated FBS.
In addition to infection, V was translocated into target host cells
by utilizing an anthrax toxin PA-LFn system instead of infection
(Ribot, unpublished data). The N-terminus region of LF (amino
acid residues 1–256 [LFn]) contains the PA binding domain. The
fusion protein used in our studies consisted of LFn fused in-frame
with the V gene. MFs were washed with 10 mM phosphate
buffered saline (PBS) and incubated with 50 mg/ml of LFnV and
3 mg/ml of PA for 4 h at 37uC (5% CO2). MFs were fixed for
15 min in 3.7% formaldehyde at 37uC (5% CO2), and were
examined by IFM, immunoblotting, and flow cytometry.
Macrophage infection and delivery of V antigen
For IFM and ICM studies, MFs were plated onto Lab-Tek II 4
and 8-well glass chamber slides (Pittsburgh, PA) or Bioptechs Delta
T cell culture dishes (Butler, PA). MFs were pretreated for 30 min
with 5 ug/ml cytoD, an inhibitor of actin polymerization, and
infected with one of the Y. pestis or Y. pseudotuberculosis strains as
described above. In experiments where SMI of T3S were utilized,
SMIs were added to Y. pestis and Y. pseudotuberculosis 30 min before
infection to prevent Yops delivery [36,43]. Samples were taken at
5, 10, 15, 30, and 45 min after infection, and cells were washed
three times with PBS. In longer incubations, MWs were infected
for 1 h, washed, then either processed directly for microscopy or
incubated with 7.5 mg/ml of gentamicin for an additional 1–5 h
for analysis. MWs were stained, fixed, and permeabilized
according to manufacturer recommendations, followed by incu-
bation with diluted mAb to V for 1 h at 37uC (5% CO2).
Chambers were removed and washed with PBS. All slides were
observed under 406,6 0 6, and 1006(oil) magnification with a
Nikon E800 series fluorescence microscope or with the BioRad
2000MP multiphoton confocal system and a Nikon TE300
inverted microscope.
The effects of mitochondrial inhibition on intracellular V
trafficking was monitored by IFM. For the mitochondrial
inhibition assays, MWs were pretreated with 5 mg/ml cytoD,
10 mM Ru360 (Calbiochem, San Diego, CA) [45], or both for
30 min prior to infection with CO92 pPst- pgm- or YpIII p(IB604)
strains for 2.5–4 h. For monitoring the trans-Golgi network, some
of the MWs were stained with WGA 1 h before infection.
Following infection, MWs were processed as previously described.
Acquired images were analyzed for co-localization as 8-bit TIFF
images in Image J software version 1.40 g (National Institutes of
Health, Washington, DC, USA), using the JACoP plugin, which
employs a three-dimensional object counter object-based tool in
addition to current statistical correlations of intensity [37]. Co-
localization was quantified by considering (1) a Pearson’s
correlation coefficient (r), and (2) a Manders overlap coefficient
(r), including a background subtraction. PCC predicts a positive
correlation as r approaches 1 and a negative correlation for values
close to -1; whereas, MOC indicates 100% co-localization at 1 and
no co-localization at 0 [37,38]. For all markers averages of three
experiments were analyzed.
IEM was performed on uninfected MFso rM Fs infected with
CO92 pPst
2 pgm
2 and then fixed in a buffer of 4%
paraformaldehyde (Sigma), 0.2% glutaraldehyde (Sigma), and
0.1 M sodium cacodylate (Ricca Chemical Co., Texas) [79]. The
samples were then embedded for thin sectioning and stained with
gold-labeled Abs to V (6 nm) and organelles (15 nm). Images were
taken at a range of 30,000–100,0006 using a JEOL JEM 1010
microscope with a Hamamatsu CCD camera.
Density gradient centrifugation and Immunoblotting
MFs were infected as described above, washed with 4uC PBS,
and incubated in a solution of organelle-specific 16 Extraction
Buffer (Organelle Isolation KitsH, Sigma Aldrich) and a 0.1%
solution of protease inhibitor cocktail (Sigma Aldrich) overnight
(ON) on ice at 4uC. Samples were homogenized on ice using a
tissue grinder, or processed on a PrecellysH 24 Homogenizer (Mo
Bio Laboratories, Inc, CA) at two 20 sec cycles of 65006g using
1.4 mm ceramic beads. Cell lysates were centrifuged at 10006g
for 10 min at 4uC. The post-nuclear supernatants were centri-
fuged at 3000–32006g for 30 min at 4uC and the pellets were
resuspended in a 0.25 M sucrose homogenization solution
containing ioxidanol Optiprep
TM (Axis-Shield, Norton, MA).
These gradient-forming suspensions were loaded into Quick-Seal
polyallomer 13.5 ml tubes (Beckman Coulter, Fullerton, CA),
forming a discontinuous gradient. The gradients were centrifuged
at 320,0006g in a Beckman VTi65.1 rotor for 3 h at 4uC. One-ml
fractions were collected from top to bottom. All fractions were
stored at 220uC until further use.
Fractions derived from ultracentrifugation were thawed on ice,
combined with lithium dodecyl sulfate (LDS) loading buffer,
NuPage reducing agent and antioxidant, and boiled before loading
onto replicate 10% NuPage Bis-Tris gels (Invitrogen) with
prelabeled Western standards (Invitrogen). The replicate gels were
electrophoresed and either stained with SimplyBlue SafeStain
(Invitrogen) or the protein bands were transferred to 0.2 mm pore
size polyvinylidene difluoride (PVDF) membranes (Invitrogen).
Membranes were blocked at 4uC in PBS with 0.2% Tween220
(Sigma Aldrich) and 7% blotting grade milk (Santa Cruz
Biotechnology, Inc.). They were washed with PBS, then incubated
1 h 15 min with a primary Ab listed in Table 1 or with polyclonal
Abs to YopM, YopH, YopE, or YopD diluted in 7% blocking
solution. Next, the membranes were washed and incubated 1.5 h
with secondary Ab conjugated to horseradish peroxidase (HRP).
The membranes were washed and incubated in a luminol/
peroxide detection solution from the SuperSignal West Pico
Chemiluminescence Substrate Kit (Pierce) for 5 min in the dark,
exposed to Kodak Biomax ML film, and developed on a Kodak
X-OMAT M20 Processor.
Organelle isolation and Flow cytometry
Before use in flow cytometry, MFs were infected as previously
described, washed five times with PBS for 5 min each, and
collected into 16Extraction Buffer with protease inhibitor cocktail
(Sigma Aldrich). MFs were observed for the amount of lysis that
occurred during the ON incubation by staining with trypan blue,
and inadequate lysis (,90%) was remedied by homogenization, as
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Endoplasmic Reticulum (ER), Peroxisome, or Lysosome Isolation
kits (Sigma Aldrich), according to manufacturer recommendations.
Proteins were isolated from the Golgi apparatus using the ER
isolation kit. All samples were electrophoresed and transferred as
described above, and the blots developed with Ab (Table 1) to
each organelle. Isolated organelle-rich samples were pooled and
stored at 4uC, 220 uC, or 270uC until used for flow cytometry
analysis, according to manufacturer recommendations.
Cell lysates or isolated organelles were fixed, permeabilized, and
stained as previously described. Samples were read on a BD
Biosciences FACSCalibur (Franklin Lakes, NJ). Regions were
drawn in accordance with samples that were stained with the
organelle-associate markers and/or with anti-V Ab. Percentages of
each region were averaged and entered into GraphPad Prism
version 5.01. A one-way ANOVA was performed, followed by
paired t-test comparisons of each region (1–3) according to each
treatment. For example, organelles stained with anti-V Abs alone
were compared with dually-stained organelles. Differences in
region 3, in particular, between anti-V Ab stained organelles and
those stained with both the organelle-associated markers and anti-
V Abs were considered statistically significant at P,0.05.
For cell viability assays, MFs were plated into 24-well cell
culture plates (Fisher Scientific) and infected as previously
described. The MFs were then washed with PBS, and stained
with (1) PI (5 mg/ml) and/or 2.5 mM Syto-13 [80], or (2)
DeadRed/Syto-10, according to manufacturer instructions (In-
vitrogen, Carlsbad, CA) at 37uC for 30 min. Samples were
centrifuged at 10006g, resuspended in PBS, and read on a BD
FACSCalibur. PI intercalates into double-stranded nucleic acids
and is excluded by viable cells, identifying dead cells by the
appearance of red fluorescent staining, as also detected by
DEADRed. In contrast, Syto binds nucleic acids of both live cells
and appears as green fluorescent staining. Flow cytometry live/
dead data from uninfected and infected MFs was entered into
GraphPad Prism. A 2-way ANOVA was performed with
Bonferroni post hoc tests. Statistically significant differences
between strains were considered when P,0.05.
Supporting Information
Figure S1 Inhibition of V Trafficking as detected by IFM. To
determine if V was trafficking from lysosomes to mitochondria and
Golgi sequentially or simultaneously, MFs were pretreated with
Ru360, an inhibitor of mitochondrial function, cytoD, or both for
30 min before infection with YpIII p(IB604) for 4 h, followed by
staining with WGA and anti-V Ab. When cyto D alone was
present, co-localization of V with Golgi protein(s) (panel A) was
observed, as observed in Fig. 1 (panels E and K). In the presence of
Ru360 alone, V staining was too intense to determine localization
(panel B). When both cytoD and Ru360 were present (panel C), no
co-localization was observed.
Found at: doi:10.1371/journal.pone.0006281.s001 (2.10 MB TIF)
Figure S2 The effect of V on cell viability as detected by flow
cytometry. MFs were infected with a V- negative strain (YpIII
p[IB19]), a T3SS inhibited strain (YpIII p[IB604]), or with intact
T3SS and V producing strains (CO92 pPst- pgm- and Y. ptb.
pTcrV), with or without SMI of T3S present prior to infection.
Percentages of live (stained with Syto) and dead (stained with PI/
DEADRed) MFs were plotted. Dead MFs from uninfected
samples ranged from ,9–11% of the total population (data not
shown). Infected MF cell death ranged from 42.24 to 72.67%.
Differences between samples were significant by ANOVA
(P,0.001). Bonferroni post hoc t-tests were performed comparing
all strains to the V-negative strain. Significant differences were
observed when MFs infected with the V-negative YpIII p(IB19)
strain were compared to those infected with CO92 pPst- pgm-
(***, P,0.001) or with Y. ptb. pTcrV (P,0.001); whereas, no
significant differences were found when MFs infected with the V-
negative strain were compared to those infected with YpIII
p(IB604) or with SMI-pretreated CO92 pPst- pgm- infected MFs.
However, when Y. ptb. pTcrV was pretreated with SMIs, there
was still a significant difference (*, P,0.05) when compared to the
V-negative strain.
Found at: doi:10.1371/journal.pone.0006281.s002 (0.81 MB TIF)
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